Background: Loss of INI1/SMARCB1 protein expression in tumor cells is characteristic of ES and impairs activity of the SWI/SNF chromatin remodeling complex inducing oncogenic dependence on EZH2. Tazemetostat, a potent, selective, orally available EZH2 inhibitor has shown clinical activity in INI1-negative tumors including durable objective responses and disease stabilization. While loss of protein expression is a key characteristic of ES, the molecular basis of loss is poorly understood; here we report genetic characterization results of the largest ES cohort to date. Methods: DNA was isolated from matched tumor and normal samples from 62 ES cases with confirmed INI1 protein loss by IHC. Sufficient DNA was isolated for WES (N ¼ 43), WGS (N ¼ 37), and DNA methylation analysis (N ¼ 35). WGS and WES were performed on tumor and matched normal samples at 30-200X and 10-50X, respectively. Results: Interim WES analysis on 19 ES cases established that SMARCB1 was the most frequently altered gene (16/19 cases). Review of 325 cancer specific genes, including all SWI/SNF complex members demonstrated that CTNNA1, LRP1B, and NOTCH1 were the next most commonly mutated genes (3/19 cases each). Additionally, the median mutation burden for ES cases was 25.8 mutations/MB suggesting a greater genetic complexity than other predominantly INI1-negative tumors (e.g. AT/RT and MRT). SMARCB1 alterations were consistent with potential causes of INI1 protein expression loss and included both large and focal chromosomal deletions (n ¼ 13), and SNVs (n ¼ 5). Evidence of SMARCB1 bi-allelic loss occurred in 7/19 ES cases, whereas 9/19 cases only had evidence of monoallelic loss. Analysis of DNA methylation data from cases with either no or monoallelic SMARCB1 loss did not support DNA methylation as a mechanism for SMARCB1 silencing. Conclusions: Alterations of SMARCB1 were the predominant genetic event observed in ES and is the underlying molecular mechanism leading to loss of INI1 protein expression. Notably, multiple genetic mechanisms leading to protein INI1 loss were detected. Updated genetic characterization data on N ¼ 43 ES cases, including analyses to explore potential genetic associations with clinical outcome will be presented.
Background: Loss of INI1/SMARCB1 protein expression in tumor cells is characteristic of ES and impairs activity of the SWI/SNF chromatin remodeling complex inducing oncogenic dependence on EZH2. Tazemetostat, a potent, selective, orally available EZH2 inhibitor has shown clinical activity in INI1-negative tumors including durable objective responses and disease stabilization. While loss of protein expression is a key characteristic of ES, the molecular basis of loss is poorly understood; here we report genetic characterization results of the largest ES cohort to date. Methods: DNA was isolated from matched tumor and normal samples from 62 ES cases with confirmed INI1 protein loss by IHC. Sufficient DNA was isolated for WES (N ¼ 43), WGS (N ¼ 37), and DNA methylation analysis (N ¼ 35). WGS and WES were performed on tumor and matched normal samples at 30-200X and 10-50X, respectively. Results: Interim WES analysis on 19 ES cases established that SMARCB1 was the most frequently altered gene (16/19 cases). Review of 325 cancer specific genes, including all SWI/SNF complex members demonstrated that CTNNA1, LRP1B, and NOTCH1 were the next most commonly mutated genes (3/19 cases each). Additionally, the median mutation burden for ES cases was 25.8 mutations/MB suggesting a greater genetic complexity than other predominantly INI1-negative tumors (e.g. AT/RT and MRT). SMARCB1 alterations were consistent with potential causes of INI1 protein expression loss and included both large and focal chromosomal deletions (n ¼ 13), and SNVs (n ¼ 5). Evidence of SMARCB1 bi-allelic loss occurred in 7/19 ES cases, whereas 9/19 cases only had evidence of monoallelic loss. Analysis of DNA methylation data from cases with either no or monoallelic SMARCB1 loss did not support DNA methylation as a mechanism for SMARCB1 silencing. Conclusions: Alterations of SMARCB1 were the predominant genetic event observed in ES and is the underlying molecular mechanism leading to loss of INI1 protein expression. Notably, multiple genetic mechanisms leading to protein INI1 loss were detected. Updated genetic characterization data on N ¼ 43 ES cases, including analyses to explore potential genetic associations with clinical outcome will be presented. Clinical trial identification: NCT02601950. Background: The dysregulated tumour metabolism is one of the hallmarks of cancer. Metabolome analysis has thus been proposed as a broadly applicable tool for diagnosis and anti-cancer treatment in various cancers, such as lung, colorectal and breast cancers. Up until now, a number of metabolic biomarkers have been reported; however, there is still little application in a clinical setting due to the fact that the metabolic approach with the clinical samples has not been generally authorized. In this study, using metabolome analysis, we determined the cancer-specific metabolites and explored the applicability of the liquid biopsy for discovering the potential biomarkers of breast cancer. Methods: A total of 22 patients with breast cancer were enrolled and their metabolite levels were analyzed with CE-MS, quantitating 511 identifiable metabolites in plasma and non-cancer/cancer tissues. Samples were immediately kept in liquid nitrogen and stored at -80˚C until further tissue processing, including removal of proteins prior to CE-MS analysis. All the available metabolite data with absolute concentration were analyzed using a web-based platform, MetaboAnalyst 4.0.
Results: A total of 511 known metabolites were measured; of these, 159 metabolite changes in concentration were observed in cancer tissues compared with in non-cancer tissues. In plasma samples, 67/159 metabolites significantly increased in cancer tissues. The affected metabolites were 2-hydroxyglutarate, succinate and fumarate, all of which are known as representative "oncometabolites" involved in tumorigenesis. Moreover, metabolites associated with purine synthesis and pyrimidine synthesis were also markedly upregulated. These cancer-related metabolic changes had correlation with the proliferation markers of cancer tissues. Conclusions: We identified for the first time the signature of metabolic reprograming between non-cancer and cancer tissues in breast cancer, and this metabolic shift was observed in plasma. The plasma levels of biomarkers relating to nucleic acid synthesis (purine and pyrimidine synthesis) was associated with the high proliferation status of breast cancer. Legal entity responsible for the study: Narumi Harada. 
